Current Status and Future Perspective of Onco-Hypertension.

Cancer Cardiovascular disease Hypertension Onco-Hypertension Oncology

Journal

American journal of hypertension
ISSN: 1941-7225
Titre abrégé: Am J Hypertens
Pays: United States
ID NLM: 8803676

Informations de publication

Date de publication:
30 Jul 2024
Historique:
received: 15 07 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: aheadofprint

Résumé

Hypertension and cancer are both increasing with age. Recently, the new concept of "Onco-Hypertension" has been proposed to address the mutual risks posed by hypertension and cancer and to provide comprehensive care for patients with these two conditions in an aging society. Hypertension and cancer share common risk factors and may be interrelated in pathogenesis: hypertension is involved in the development of certain cancers, and cancer survivors have a higher incidence of hypertension. With recent advances in cancer therapy, the number of cancer survivors has increased. Cancer survivors not only have a higher risk of incident hypertension but also an increased risk of future cardiovascular events, highlighting the growing importance of comprehensive care. In this review, we provide an overview of the current status and future perspective of the "Onco-Hypertension," including our research findings.

Identifiants

pubmed: 39078615
pii: 7724082
doi: 10.1093/ajh/hpae099
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

Auteurs

Tatsuhiko Azegami (T)

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Hidehiro Kaneko (H)

Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.

Shintaro Minegishi (S)

Department of Cardiology, Yokohama City University School of Medicine, Yokohama, Japan.

Yuta Suzuki (Y)

Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.

Hiroyuki Morita (H)

Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.

Katsuhito Fujiu (K)

Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.

Norihiko Takeda (N)

Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.

Takashi Yokoo (T)

Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.

Yuichiro Yano (Y)

Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
Noncommunicable Disease (NCD) Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.

Kaori Hayashi (K)

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Akira Nishiyama (A)

Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Koichi Node (K)

Department of Cardiovascular Medicine, Saga University, Saga, Japan.

Classifications MeSH